Aktuellt
SENASTE
Redeye endorses SenzaGen’s new order from a global biotech industry leader. We highlight the order value of SEK1.7m and argue it should be considered as high as it is from a new customer. We reiterate our base case of SEK20 and argue the SenzaGen share is currently traded at attractive levels.
LÄS MER
